Natco Pharma up 20% as Mylan gets USFDA nod for generic Glatiramer Acetate

The stock up 20% to Rs 954 on BSE after the company said its marketing partner Mylan receives final approval of generic Glatiramer Acetate, for both 20 mg/mL and 40 mg/mL versions.

Natco Pharma is locked in maximum upper limit of day, up 20% to Rs 954 on BSE after the company said its marketing partner Mylan has received final approval of generic Glatiramer Acetate, for both 20 mg/mL and 40 mg/mL versions.

The trading volumes on the counter jumped more than four-fold with a combined 548,773 shares exchanging hands on BSE and NSE till 09:28 AM. There were pending buy orders for 610,513 shares on both the exchanges.

“The U.S. Food and Drug Administration (FDA) has approved its marketing partner Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate